SeaStar Medical Holding Corporation (ICU) Q3 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

reducing the amount of cash we need to raise to fund operations. Now, turning our efforts on the neutralized AKI trial, we completed the interim analysis, enabling us to understand early safety data and trends toward efficacy for our neutralized AKI pivotal trial of the selective cytophoretic device or SCD therapy. We also continue to add clinical sites to ensure we meet our new enrollment targets for the trial. In addition, We also announced today that we have opened the first site for the neutralized CRS clinical trial of the SCD therapy to treat patients with acute chronic systolic heart failure with cardiorenal syndrome, or CRS, awaiting left ventricular assist device, or LVAD, implantation. This is a small but very important market opportunity as it would potentially demonstrate the value of the SCD therapy in an indication outside of AKI. supporting its broad applications in many destructive hyper-inflammation conditions. Finally, we continued our disciplined effort to reduce costs while achieving strong operational results, and we raised over $12 million to strengthen our balance sheet and extend our financial runway. Now, before I turn the call over to Tim, I'd like to emphasize one last point. That is, the data we see and the stories we hear about how quell immune therapy has saved the lives of critically ill pediatric patients who in most cases have little hope of survival, are what drives our efforts to expand the use of this therapy to more children and to adults with similar conditions caused by destructive hyperinflammation. These market opportunities are significant, and we are working diligently to bring our lifesaving therapy to the patients whose chances of survival due to hyperinflammation are otherwise limited. And now, I will turn the call over t...